Sugi Predict

Sugi Predict / Compounds / SCHEMBL7896877

SCHEMBL7896877

SCHEMBL7896877

COC(=O)Cc1ccc(OC)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ GAA P10253 3/20 0.51
▸ GFER P55789 1/20 0.51
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ POLB P06746 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CYP4F2 P78329 1/20 0.49
▸ CYP4A11 Q02928 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ HSP90AB1 P08238 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30154470 0.87 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2GAAGFERCA1
SCHEMBL2982711 0.87 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2GAAGFERCA1
SCHEMBL21820674 0.86 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2GAAGFERCA1
SCHEMBL3616256 0.85 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2GAACA1CA2
SCHEMBL4086439 0.85 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2GAACA1CA2
SCHEMBL921998 0.85 GAA (0.68) ALDH1A1SMN1; SMN2GAACA1CA2
SCHEMBL198282 0.84 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2GAAGFERCA2
SCHEMBL29626821 0.84 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2GAAGFERCA2
SCHEMBL298044 0.84 TSHR (0.62) ALDH1A1SMN1; SMN2GAAGFERHSD17B10
SCHEMBL30632630 0.84 TSHR (0.62) ALDH1A1SMN1; SMN2GAAGFERHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 — — US disclosed
CN-109890822-B Inhibitors of cellular metabolic processes 安吉奥斯医药品有限公司 2022-08-30 — — CN disclosed
US-11325914-B1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2022-05-10 — — US disclosed
US-10961266-B2 Chemoselective methylene hydroxylation in aromatic molecules THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-03-30 — — US disclosed
US-10800782-B2 Inhibitors of cellular metabolic processes Agios Pharmaceutical, Inc. (US) 2020-10-13 — — US disclosed
US-20200087331-A1 CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2020-03-19 — — US disclosed
US-20190233424-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2019-08-01 — — US disclosed
EP-3507290-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES Agios Pharmaceuticals, Inc. (US) 2019-07-10 — — EP disclosed
US-10329298-B2 Inhibitors of cellular metabolic processes AGIOS PHARMACEUTICALS, INC. (US) 2019-06-25 — — US disclosed
CN-109890822-A INHIBITORS OF CELLULAR METABOLIC PROCESSES 安吉奥斯医药品有限公司 2019-06-14 — — CN disclosed
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES SERVIER PHARMACEUTICALS LLC 2018-03-22 — — US disclosed
WO-2018045071-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES AGIOS PHARMACEUTICALS, INC. (US) 2018-03-08 — — WO disclosed
CN-1151155-C 1, 5-dihydro-pyrazolo [3, 4-D ] -pyrimidone derivatives — 2004-05-26 — — CN disclosed
US-6174884-B1 CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2001-01-16 — — US disclosed
CN-1255133-A 1,5-dihydro-pyrazolo [3,4-D]-pyrimidinone derivatives BAYER AG (DE) 2000-05-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961266-B2 Chemoselective methylene hydroxylation in aromatic molecules PAH, DBH, AHR ALDH1A1 415/4885SMN1; SMN2 2130/4885GAA 1030/4885
US-20200087331-A1 CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES PAH, DBH, AHR ALDH1A1 415/4885SMN1; SMN2 2130/4885GAA 1030/4885
US-10329298-B2 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 ALDH1A1 352/4885SMN1; SMN2 2162/4885GAA 968/4885
US-20190233424-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES MNAT1, MAT2A, PCK2 ALDH1A1 352/4885SMN1; SMN2 2162/4885GAA 968/4885
US-10800782-B2 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 ALDH1A1 352/4885SMN1; SMN2 2162/4885GAA 968/4885
US-20180079753-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES MNAT1, MAT2A, PCK2 ALDH1A1 352/4885SMN1; SMN2 2162/4885GAA 968/4885
US-11325914-B1 Inhibitors of cellular metabolic processes MNAT1, MAT2A, PCK2 ALDH1A1 352/4885SMN1; SMN2 2162/4885GAA 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.